Fed. Circ. Backs Amgen's $70M Patent Win Over Epogen
Law360 (December 16, 2019, 5:18 PM EST) -- The Federal Circuit on Monday affirmed Amgen's $70 million victory over its anemia treatment Epogen, ruling the jury correctly found that Hospira was not shielded by a safe harbor meant for companies seeking federal approval for biosimilar products.
The Federal Circuit backed a $70 million patent infringement verdict that Amgen won against Hospira in what was one of the first trials to test the rules for developing biosimilars. (Getty)
In a published opinion, the three-judge panel affirmed a Delaware federal court's decision to uphold a jury verdict that Pfizer Inc. unit Hospira Inc. infringed Amgen Inc.'s patent covering the creation of...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!